Skip to Main Content

Advertisement

Skip Nav Destination

Robert E. Marcus, MD: GALLIUM Study of Obinutuzumab in Untreated Follicular Lymphoma

December 30, 2021

Results from the GALLIUM trial, which were presented as a Late-Breaking Abstract at the 2016 ASH Annual Meeting, showed that first-line treatment with obinutuzumab led to longer progression-free survival than rituximab.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X